Table 7.
Effect of adding oxaliplatin for high-risk patients on survival in multivariate analysis
| Alive (n=1,054) | Death (n=105) | HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Regimen | ||||||
| 5-FU/leucovorin or capecitabine or UFT/leucovorin or LV5FU2 | 536 (90.5) | 56 (9.5) | Reference | Reference | ||
| FLOX or FOLFOX or mFOLFOX | 518 (91.4) | 49 (8.6) | 0.97 (0.66-1.43) | 0.882 | 1.36 (0.91-2.03) | 0.132 |
| Age (yr) | ||||||
| ≤ 45 | 72 (97.3) | 2 (2.7) | Reference | Reference | ||
| > 45 and ≤ 70 | 660 (94.0) | 42 (6.0) | 2.27 (0.55-9.35) | 0.258 | 2.30 (0.56-9.51) | 0.251 |
| > 70 | 322 (84.1) | 61 (15.9) | 6.58 (1.61-26.88) | 0.009 | 6.41 (1.54-26.66) | 0.011 |
| ASA | ||||||
| I-II | 911 (92.5) | 74 (7.5) | Reference | Reference | ||
| III | 136 (82.4) | 29 (17.6) | 2.68 (1.74-4.12) | < 0.001 | 1.98 (1.27-3.08) | 0.003 |
| IV | 7 (77.8) | 2 (22.2) | 4.25 (1.04-17.36) | 0.044 | 3.19 (0.78-13.08) | 0.107 |
HR, hazard ratio; CI, confidence interval; FU, fluorouracil; UFT, tegafur-uracil; LV, leucovorin; FLOX, fluorouracil, leucovorin, and oxaliplatin; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; mFOLFOX, modified FOLFOX regimen; ASA, American Society of Anesthesiologists.